Skip to content
10-K

Annual Report

Oruka Therapeutics, Inc. ORKA

0001213900-26-026929

← back to feed
Filed
Mar 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 28, 2026 49.54M sh
Capex FY 2025 · Dec 31, 2025 $209K
Capex FY 2025 · Dec 31, 2024 $189K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$88.21M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$57.84M
Cash And Equivalents FY 2025 · Dec 31, 2025 $46.94M
Cash And Equivalents FY 2025 · Dec 31, 2024 $61.58M
Stockholders Equity FY 2025 · Dec 31, 2025 $471.93M
Stockholders Equity FY 2025 · Dec 31, 2024 $382.22M
Stockholders Equity FY 2025 · Feb 6, 2024 $1K
Current Liabilities FY 2025 · Dec 31, 2025 $15.37M
Current Liabilities FY 2025 · Dec 31, 2024 $13.04M
Total Liabilities FY 2025 · Dec 31, 2025 $16.69M
Total Liabilities FY 2025 · Dec 31, 2024 $13.8M
Current Assets FY 2025 · Dec 31, 2025 $343.86M
Current Assets FY 2025 · Dec 31, 2024 $376.87M
Total Assets FY 2025 · Dec 31, 2025 $488.62M
Total Assets FY 2025 · Dec 31, 2024 $396.02M
Rd Expense FY 2025 · Dec 31, 2025 $100.64M
Rd Expense FY 2025 · Dec 31, 2024 $75.06M
Net Income FY 2025 · Dec 31, 2025 −$105.43M
Net Income FY 2025 · Dec 31, 2024 −$83.72M
Net Income FY 2025 · Dec 31, 2024 −$83.72M
Operating Income FY 2025 · Dec 31, 2025 −$122.05M
Operating Income FY 2025 · Dec 31, 2024 −$88.12M